298538: [三井康裕]/[佐藤康史]/[宮本弘志]/[藤野泰輝]/Takaoka Toshi/[三好人正]/Kagawa Miwako/Ohnuma Hiroyuki/Hirakawa Masahiro/Kubo Tomohiro/Osuga Takahiro/Sagawa Tamotsu/Sato Yasuhiro/Takahashi Yasuo/Katsuki shinichi/Okuda Toshinori/Takimoto Rishu/Kobune Masayoshi/Nobuoka Takayuki/Hirata Koichi/Kato Junji/[高山哲治]/Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy./[Cancer Chemotherapy and Pharmacology]

著作: [三井康裕]/[佐藤康史]/[宮本弘志]/[藤野泰輝]/Takaoka Toshi/[三好人正]/Kagawa Miwako/Ohnuma Hiroyuki/Hirakawa Masahiro/Kubo Tomohiro/Osuga Takahiro/Sagawa Tamotsu/Sato Yasuhiro/Takahashi Yasuo/Katsuki shinichi/Okuda Toshinori/Takimoto Rishu/Kobune Masayoshi/Nobuoka Takayuki/Hirata Koichi/Kato Junji/[高山哲治]/Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy./[Cancer Chemotherapy and Pharmacology]

ヘルプを読む

「著作」（著作（著書，論文，レター，国際会議など））は，研究業績にかかる著作（著書，論文，レター，国際会議など）を登録するテーブルです． (この情報が属するテーブルの詳細な定義を見る)

項目名の部分にマウスカーソルを置いて少し待つと，項目の簡単な説明がツールチップ表示されます．

この情報をEDB閲覧画面で開く

EID: 298538
EOID: 842773
Map: 0
LastModified: 2016年12月21日(水) 11:44:15
Operator: 高山哲治
Avail: TRUE
Censor: 0
Owner: 高山哲治
Read: 継承
Write: 継承
Delete: 継承

種別

必須

学術論文(審査論文)

言語

必須

英語

招待

推奨

審査

推奨

カテゴリ

推奨

共著種別

推奨

学究種別

推奨

組織

推奨

著者

必須

三井康裕([徳島大学.大学院医歯薬学研究部.医学域.先端医学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])

役割任意

貢献度任意

学籍番号推奨
佐藤康史([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])

役割任意

貢献度任意

学籍番号推奨
宮本弘志([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学]/[徳島大学.病院.診療科.内科.消化器内科])

役割任意

貢献度任意

学籍番号推奨
藤野泰輝

役割任意

貢献度任意

学籍番号推奨
(英) Takaoka Toshi

役割任意

貢献度任意

学籍番号推奨
三好人正

役割任意

貢献度任意

学籍番号推奨
(英) Kagawa Miwako

役割任意

貢献度任意

学籍番号推奨
(英) Ohnuma Hiroyuki

役割任意

貢献度任意

学籍番号推奨
(英) Hirakawa Masahiro

役割任意

貢献度任意

学籍番号推奨
(英) Kubo Tomohiro

役割任意

貢献度任意

学籍番号推奨
(英) Osuga Takahiro

役割任意

貢献度任意

学籍番号推奨
(英) Sagawa Tamotsu

役割任意

貢献度任意

学籍番号推奨
(英) Sato Yasuhiro

役割任意

貢献度任意

学籍番号推奨
(英) Takahashi Yasuo

役割任意

貢献度任意

学籍番号推奨
(英) Katsuki shinichi

役割任意

貢献度任意

学籍番号推奨
(英) Okuda Toshinori

役割任意

貢献度任意

学籍番号推奨
(英) Takimoto Rishu

役割任意

貢献度任意

学籍番号推奨
(英) Kobune Masayoshi

役割任意

貢献度任意

学籍番号推奨
(英) Nobuoka Takayuki

役割任意

貢献度任意

学籍番号推奨
(英) Hirata Koichi

役割任意

貢献度任意

学籍番号推奨
(英) Kato Junji

役割任意

貢献度任意

学籍番号推奨
高山哲治([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])

役割任意

貢献度任意

学籍番号推奨

題名

必須

(英) Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.

副題

任意

要約

任意

(英) We previously reported that a triplet combination of docetaxel, cisplatin, and S-1 (DCS) is active against metastatic gastric cancer with a very high response rate of 87.1 % in a phase II study. Recently, the efficacy of trastuzumab (T-mab) for the treatment of HER2-positive gastric cancer has been reported. Therefore, we investigated the feasibility and preliminary efficacy of DCS + T-mab (DCS-T) for unresectable HER2-positive metastatic gastric cancer. Patients received oral S-1 (40 mg/m(2) b.i.d.) on days 1-14, intravenous cisplatin (60 mg/m(2)), docetaxel (50 mg/m(2)), and T-mab (8 mg/kg in the first cycle and 6 mg/kg in the second cycle and thereafter) on day 8 every 3 weeks. The study included 16 patients: median age, 60 (34-76) years; males/females, 11:5; intestinal-type/diffuse-type histology, 11:5; and HER2 3+/2+(FISH+), 13:3. The completion rate until the third cycle was 87.5 % (14/16) (95 %CI 71.3-103.7 %). Adverse events of grade 3/4 severity during the first 3 cycles were: leukopenia/neutropenia, 50.0:75.0 %; febrile neutropenia, 12.5 %; diarrhea, 12.5 %; and stomatitis, 12.5 %. All of these side effects were manageable and well controlled. There were no treatment-related deaths. The overall response rate was 93.8 % (15/16), and the response rate in patients with measurable lesions was 100 % (15/15). The median cycle to response was only 1 (1-3 cycles). Non-curative factors disappeared in 56.3 % (9/16) of patients, and conversion surgery (R0 resection) was performed in all these cases. Pathological response rates in primary and metastatic lesions were 88.9 % (8/9) and 100 % (9/9), respectively. The median PFS and OS were not reached during the median follow-up time of 18.3 months ranged from 11.0 to 34.3 months. DCS-T was feasible in patients with unresectable HER2-positive metastatic gastric cancer. The observed response was very promising and warrants further investigation. UMIN000005603.

キーワード

推奨

(英) Adult
(英) Aged
(英) Antibodies, Monoclonal, Humanized
(英) Cisplatin
(英) Drug Combinations
(英) Feasibility Studies
(英) Female
(英) Humans
(英) Male
(英) Middle Aged
(英) Neoplasm Metastasis
(英) Oxonic Acid
(英) Receptor, Epidermal Growth Factor
(英) Stomach Neoplasms
(英) Taxoids
(英) Tegafur

発行所

推奨

誌名

必須

Cancer Chemotherapy and Pharmacology([Springer-Verlag])

(pISSN: 0344-5704, eISSN: 1432-0843)

ISSN	任意	1432-0843 ISSN: 0344-5704 (pISSN: 0344-5704, eISSN: 1432-0843) Title: Cancer chemotherapy and pharmacology Title(ISO): Cancer Chemother Pharmacol Supplier: Springer Online Journal Archive Publisher: Springer (NLM Catalog) (Scopus) (CrossRef) (Scopus information is found. [need login])

巻

必須

号

必須

頁

必須

375 382

都市

任意

年月日

必須

2015年 6月 23日

URL

任意

DOI

任意

10.1007/s00280-015-2807-7 (→Scopusで検索)

PMID

任意

26099968 (→Scopusで検索)

CRID

任意

WOS

任意

000358581900017

Scopus

任意

2-s2.0-84938207398

評価値

任意

被引用数

任意

指導教員

推奨

備考

任意

(英) Article.ELocationID: 10.1007/s00280-015-2807-7
(英) Article.PublicationTypeList.PublicationType: Clinical Trial
(英) Article.PublicationTypeList.PublicationType: Journal Article
(英) Article.PublicationTypeList.PublicationType: Multicenter Study
(英) Article.PublicationTypeList.PublicationType: Research Support, Non-U.S. Gov't

徳島大学教育・研究者情報データベース(EDB)

Education and Research Database (EDB), Tokushima University